130 related articles for article (PubMed ID: 38883398)
21. Progressive kaposiform hemangioendothelioma and sirolimus-related severe thrombocytopenia.
Ying H; Qiao C; Wang L; Lin X
Indian J Dermatol Venereol Leprol; 2023; 89(1):54-59. PubMed ID: 36688881
[TBL] [Abstract][Full Text] [Related]
22. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma.
Peng S; Yang K; Xu Z; Chen S; Ji Y
J Paediatr Child Health; 2019 Sep; 55(9):1119-1124. PubMed ID: 30604513
[TBL] [Abstract][Full Text] [Related]
23. First Intracardiac Kaposiform Hemangioendothelioma in an Infant Resolved With Sirolimus: A Case Report.
Zaidi SJ; Shaik S; Agrawal C; Cossor W
J Pediatr Hematol Oncol; 2018 Oct; 40(7):536-540. PubMed ID: 30067556
[TBL] [Abstract][Full Text] [Related]
24. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
Hermans DJ; van Beynum IM; van der Vijver RJ; Kool LJ; de Blaauw I; van der Vleuten CJ
J Pediatr Hematol Oncol; 2011 May; 33(4):e171-3. PubMed ID: 21516018
[TBL] [Abstract][Full Text] [Related]
25. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Apr; 62(4):577-80. PubMed ID: 25346262
[TBL] [Abstract][Full Text] [Related]
26. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma.
Liu YX; Zhang J; Nie XL; Chen YL; Wang ZY; Xu ZG
Australas J Dermatol; 2021 May; 62(2):e329-e331. PubMed ID: 33216947
[No Abstract] [Full Text] [Related]
27. A not so harmless mass: Kaposiform hemangioendothelioma complicated by a Kasabach-Merritt phenomenon.
Tribolet S; Hoyoux C; Boon LM; Cheruy C; Demarche M; Jamblin P; Roberti A; Willemaers V; Viellevoye R; Rigo V; Broux I
Arch Pediatr; 2019 Sep; 26(6):365-369. PubMed ID: 31353149
[TBL] [Abstract][Full Text] [Related]
28. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.
Iacobas I; Simon ML; Amir T; Gribbin CE; McPartland TG; Kaufman MR; Calderwood S; Nosher JL
Clin Imaging; 2015; 39(3):529-32. PubMed ID: 25662209
[TBL] [Abstract][Full Text] [Related]
29. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
[No Abstract] [Full Text] [Related]
31. NEWBORNS WITH KASABACH-MERRITT PHENOMENON-ASSOCIATED KAPOSIFORM HEMANGIOENDOTHELIOMA: A REPORT OF 6 CASES.
Benzar IM; Rebenkov SO; Levytskyi AF; Fedoniuk LY; Fomina LV; Sas LM; Stravskyy TY
Wiad Lek; 2020; 73(8):1785-1789. PubMed ID: 33055352
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
33.
Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
[TBL] [Abstract][Full Text] [Related]
34. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
[No Abstract] [Full Text] [Related]
35. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Wang Z; Li K; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2014 Aug; 61(8):1518-9. PubMed ID: 24482015
[No Abstract] [Full Text] [Related]
36. Kaposiform hemangioendothelioma arising in the deltoid muscle without the Kasabach-Merritt phenomenon.
Tamai N; Hashii Y; Osuga K; Chihara T; Morii E; Aozasa K; Yoshikawa H
Skeletal Radiol; 2010 Oct; 39(10):1043-6. PubMed ID: 20309545
[TBL] [Abstract][Full Text] [Related]
37. Kaposiform hemangioendothelioma presented with raynaud phenomenon: a case report.
Liu L; Gu W; Teng L; Xu Y; Zheng F; Hu M; Lu M; Xu X
BMC Pediatr; 2023 Nov; 23(1):574. PubMed ID: 37978357
[TBL] [Abstract][Full Text] [Related]
38. Kaposiform Hemangioendothelioma Presenting as Hydrops Fetalis.
Sobrino-Fernández E; Campos-Domínguez M; Gregorio-Hernández R; Huerta-Aragonés J; Beléndez-Bieler C; Lancharro-Zapata Á; Franco-Fernández ML; Bernardo-Atienza B; Sánchez-Luna M
Pediatr Dermatol; 2017 May; 34(3):e128-e129. PubMed ID: 28318049
[TBL] [Abstract][Full Text] [Related]
39. Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report.
Cheng J; Zou Y; Fu R; Jin P; Huang M; Wu Z; Bai H; Huang X; Yuan H
Medicine (Baltimore); 2024 Apr; 103(14):e37706. PubMed ID: 38579031
[TBL] [Abstract][Full Text] [Related]
40. Successful Management of Pancreatic Kaposiform Hemangioendothelioma With Sirolimus: Case Report and Literature Review.
Wang C; Li Y; Xiang B; Li F; Chen S; Li L; Ji Y
Pancreas; 2017; 46(5):e39-e41. PubMed ID: 28426496
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
